SMA – THERAPY: P.271 FIREFISH Parts 1 and 2: 12-month pooled safety and efficacy outcomes of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA)

https://doi.org/10.1016/j.nmd.2020.08.270Get rights and content

References (0)

Cited by (0)

View full text